Table 1.
Association between alcohol consumption and liver injury indicators, after adjustment for HCV status, among HIV-infected patients receiving ART (ANRS CO8 APROCO-COPILOTE cohort—random effects logistic models, all patients—n=1154, follow-up period M0–M132)
| ALT>50 IU/l & AST/ALT>1 |
ALT>50 IU/l & AST/ALT>2 |
||||
|---|---|---|---|---|---|
| AOR (95%CI) | p-value | AOR (95%CI) | p-value | ||
| Alcohol consumption* | |||||
| abstainers (ref.) | 1 | 1 | |||
| ≤1 AU/day | 0.7 (0.5–1.2) | 0.228 | 2.8 (0.4–18.4) | 0.292 | |
| >1 and ≤4(3) AU/day for men(women) | 1.0 (0.6–1.8) | 0.847 | 0.7 (0.0–10.1) | 0.772 | |
| >4(3) AU/day for men(women) | 4.9 (2.4–9.8) | <10−3 | 29.0 (3.4–250) | 0.002 | |
| HCV infection at M0 | 12.9 (7.6–21.8) | <10−3 | 11.2 (2.7–46.4) | 0.001 | |
ALT, alanine transaminase; ART, antiretroviral therapy; AOR, adjusted OR from a random effects logistic model; AST, aspartate transaminase; AU, alcohol unit; HCV, hepatitis C virus.
*Time-varying variable (the last available value before each visit).